Reduced oral bioavailability w/ food & grapefruit juice. Potential decreased plasma conc w/ OATP1A2 substrates/inhibitors eg, ritonavir/rifampicin. Increased AUC & C
max w/ ketoconazole or erythromycin. Potential increased plasma conc w/ other medicinal products that are P-gp substrates or inhibitors eg, cyclosporine. Increased C
max w/ diltiazem. Concomitant use w/ alcohol.